M

Mid Atlantic Retina | Philadelphia/Wills Eye Hospital

Research site
(Unclaimed)
Location
840 Walnut Street, Suite 1020, Philadelphia, Pennsylvania, United States of America
Site insights

Top conditions

Macular Degeneration (29 trials)

Geographic Atrophy (11 trials)

Atrophy (10 trials)

Wet Macular Degeneration (7 trials)

Macular Edema (7 trials)

Top treatments

Ranibizumab
Lampalizumab
Aflibercept
timolol
Faricimab
Dorzolamide
Zimura
Brimonidine
Avacincaptad pegol
Timolol

Parent organization

This site is a part of Mid Atlantic Retina

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 49
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Locations recently updated

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subj...

Active, not recruiting
Dry Age-related Macular Degeneration
Drug: GT005: Medium Dose
Drug: GT005: High Dose

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been tr...

Invitation-only
Age Related Macular Degeneration (AMD)
Genetic: GT005

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Zifibancimig
Device: Port Delivery Platform

To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disea...

Active, not recruiting
Stargardt Disease 1
Other: Sham
Drug: Zimura

Trial sponsors

Roche logo

Roche (13 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems